통증 관리 의약품 시장 : 예측(2025-2030년)

The Pain Management Drugs Market is projected to climb from USD 91.628 billion in 2025 to USD 116.412 billion by 2030, fueled by a 4.90% CAGR.

The pain management drugs market is a critical segment of the pharmaceutical industry, addressing the growing need for effective pain relief solutions. Driven by an aging global population, increasing prevalence of chronic diseases, and rising surgical procedures, the market is poised for significant growth. However, the availability of alternative pain relief devices poses a challenge to market expansion.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the pain management drugs market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global pain management drugs value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 78.5 billion in 2024 and is projected to reach USD 112.3 billion by 2030, growing at a CAGR of 6.2%. Key players profiled include those leading in the production of opioids, NSAIDs, corticosteroids, antidepressants, and anticonvulsants.

Key Highlights

• Geriatric Population Growth: An aging population, reaching 1.5 billion by 2050, drives demand for pain management drugs for joint and chronic conditions.
• Chronic Disease Prevalence: Rising cases of chronic diseases, affecting 60% of adults globally in 2024, fuel market growth.
• Healthcare Expenditure: Increased spending, particularly in North America, supports advanced pain management solutions.
• Alternative Devices: Pain relief devices, gaining 8% market share in 2024, restrain drug market growth.

Growth Drivers

The growing geriatric population, with 20% of adults over 65 experiencing chronic pain in 2024, significantly boosts demand for pain management drugs. The prevalence of chronic diseases, such as rheumatoid arthritis and cancer, drives the need for targeted therapies like NSAIDs and biologics. Rising healthcare expenditure, with the U.S. allocating USD 4.5 trillion to healthcare in 2024, supports access to advanced treatments. Increasing surgical procedures, up 6% globally in 2024, heighten demand for post-operative pain relief.

Restraints

The growing adoption of pain relief devices, such as TENS units, competes with pharmaceutical solutions, impacting drug sales. Stringent regulations on opioid use, tightened in the EU and U.S. in 2024, limit prescriptions due to addiction concerns. High development costs for new formulations, averaging USD 1 billion, pose barriers for manufacturers.

Segmentation Analysis

By Drug Type: NSAIDs dominate with a 40% share in 2024, driven by widespread use for musculoskeletal pain. Biologics grow rapidly for targeted chronic pain management.

By Indication: Chronic back pain leads, followed by cancer and post-operative pain, with rheumatoid arthritis gaining traction.

By Geography: North America holds a 45% share, driven by U.S. healthcare spending and chronic disease prevalence.

Regional Analysis

North America commands a significant 45% market share in 2024, bolstered by U.S. healthcare investments and effective disease management. Asia Pacific grows at a 7.5% CAGR, driven by rising chronic disease cases and healthcare infrastructure development in China and India. Europe sustains growth through supportive healthcare policies.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in chronic disease management and innovative formulations while addressing challenges from alternative devices and regulatory constraints. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential pharmaceutical sector.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Drug Type

• Opioids
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids
• Acetaminophen
• Antidepressants
• Anticonvulsant drugs
• Local Anaesthetics
• Others

By Indication

• Cancer Pain
• Rheumatoid Arthritis
• Chronic Back Pain
• Post-Operative Pain
• Migraine and Headache Disorders
• Others

By Drug Delivery

• Oral
• Injectable
• Topical
• Transdermal
• Inhalation
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

• 5.1. Introduction
• 5.2. Opioids
• 5.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
• 5.4. Corticosteroids
• 5.5. Acetaminophen
• 5.6. Antidepressants
• 5.7. Anticonvulsant drugs
• 5.8. Local Anaeshtehtics
• 5.9. Others

6. PAIN MANAGEMENT DRUGS MARKET BY INDICATION

• 6.1. Introduction
• 6.2. Cancer Pain
• 6.3. Rheumatoid Arthritis
• 6.4. Chronic Back Pain
• 6.5. Post-Operative Pain
• 6.6. Migraine and Headache Disorders
• 6.7. Others

7. PAIN MANAGEMENT DRUGS MARKET BY DRUG DELIVERY

• 7.1. Introduction
• 7.2. Oral
• 7.3. Injectable
• 7.4. Topical
• 7.5. Transdermal
• 7.6. Inhalation
• 7.7. Others

8. PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies
• 8.5. Specialty Pharmacies

9. PAIN MANAGEMENT DRUGS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. United Kingdom
  • 9.4.2. Germany
  • 9.4.3. France
  • 9.4.4. Italy
  • 9.4.5. Spain
  • 9.4.6. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. Japan
  • 9.6.3. India
  • 9.6.4. South Korea
  • 9.6.5. Taiwan
  • 9.6.6. Thailand
  • 9.6.7. Indosneisa
  • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Novartis AG
• 11.2. Eli Lilly and Company
• 11.3. Pfizer Inc.
• 11.4. GlaxoSmithKline plc
• 11.5. Merck & Co., Inc.
• 11.6. Sanofi S.A.
• 11.7. Abbott Laboratories
• 11.8. Johnson & Johnson
• 11.9. Endo International PLC
• 11.10. Viatris Inc.
• 11.11. Purdue Pharma L.P.
• 11.12. Teva Pharmaceuticals Industries Ltd.

12. RESEARCH METHODOLOGY